Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Re-Named Melinta Moving Ahead With Delafloxacin And Novel Class Of Antibiotics

This article was originally published in The Pink Sheet Daily

Executive Summary

Formerly known as Rib-X Pharmaceuticals, Connecticut biotech reacquires rights to RX-04 antibiotic platform from Sanofi and moves forward with venture backing from Vatera and new management team.

Advertisement

Related Content

Melinta To Launch First Commercial Drug Baxdela Independently
Financings Of The Fortnight And The Never-Ending Venture Round
Antibiotic Development Incentives Face Critical Test As NDA Reviews Begin
Antibiotic Development Incentives Face Critical Test As NDA Reviews Begin
Without an IPO, Rib-X Raises $67.5 Million In Venture Funding
Rib-X Counting On Rational Drug Design To Outsmart Resistant Bacteria
Rib-X Teams With Sanofi To Develop Novel, Broad-Spectrum Antibiotics

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS074992

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel